Skip to content
MarketScale
‹ Back to IndustriesSciences

Made in America: Garrett Metal Detectors

For more than five decades, Garrett Metal Detectors has called Garland, Texas home, becoming an integral part of the community. Increasingly, Garrett products are also a part of your everyday life – chances are you’ve utilized one of their products without even knowing it, as the company’s detectors have played a critical role in…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Zach Werblo · Bob Podhrasky VideoGarrett Metal DetectorsMade in AmericaTyler Kern Video
Share

Key takeaways

01

For more than five decades, Garrett Metal Detectors has called Garland, Texas home, becoming an integral part of the community.

02

Increasingly, Garrett products are also a part of your everyday life – chances are you’ve utilized one of their products without even knowing it, as the company’s detectors have played a critical role in…

For more than five decades, Garrett Metal Detectors has called Garland, Texas home, becoming an integral part of the community.

Increasingly, Garrett products are also a part of your everyday life – chances are you’ve utilized one of their products without even knowing it, as the company’s detectors have played a critical role in keeping airports, stadiums and more, secure.

Digging Up History

Garrett detectors have also played their own role in uncovering history. On the company campus in Garland, they have established a museum full of artifacts discovered by Garrett detectors. It is full of everything from Native American hoards and Civil War artifacts, to ore deposits, World War II hand grenades, and more.

While this look into the past highlights the history of Garrett Metal Detectors, it also plays a role in preserving and telling the history of metal detecting itself.

Founder Charles Garrett exemplified the spirit of discovery that many associate with Garrett detectors, frequently taking his family on trips to see what pieces of history they could dig up themselves.

It’s that passion for adventure, and the inspiration that struck Charles Garrett when he viewed the movie “Treasure Island,” that his son, Vaughan Garrett, said sparked his father’s initial desire to found Garrett Metal Detectors.

Discovering Garland

On this episode of Made in America, host Tyler Kern gets a glimpse at not only how Garrett Metal Detectors is committed to preserving its own slice of history and its local roots, but how the company manufactures the machines that both keep us safe and help other treasure seekers forge their own.

As Garland looks toward the future, the passion and growth that will continue to buoy the city are easy to find – they are right there in Garrett Metal Detectors’ rich and storied history.

Watch Previous Episodes!

About the author

Zach Werblo
Zach WerbloDirector, Platform, BMS CAT

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Zach Werblo
Zach Werblo

Director, Platform

BMS CAT